About Us
Automating the life science labs of the future
BICO serves the world’s leading pharma and biotech companies with solutions that transform how labs operate and innovate. Our portfolio ranges from Biosero’s market-leading Green Button Go software, enabling full lab orchestration, to off-the-shelf automation products and bioprinting from our Life Science Solutions business.
Today, many researchers still spend too much time on manual tasks and fragmented data, resulting in wasted samples and stalled projects. This leads to pharma and biotech companies facing the same fundamental challenge of long, costly development cycles for new therapies. Our goal is clear: to help labs of all scales operate smarter and faster. For us, automation isn’t just about efficiency. It’s about empowering scientists to accelerate innovation and deliver breakthroughs that shape healthier societies.
Lab automation is a necessity for the future of discovery, and we at BICO are proud to play a key role in supporting this future.
Mission
Be the first-choice lab automation partner and provider of selected workflows to pharma and biotech
Vision
BICO enables and automates the life science lab of the future
OUR STORY
BICO was founded as CELLINK in the spring of 2015 in Gothenburg, Sweden, by Erik Gatenholm and Héctor Martínez. The company was built on research at Chalmers University of Technology, where Professor Paul Gatenholm had developed revolutionary bioinks. Bioinks are hydrogel-based materials that allow living human cells to be printed into 3D structures using bioprinting. In January 2016 the official company was registered with the joining of Jockum Svanberg, Ida Henriksson, and Gusten Danielsson.
Erik Gatenholm recognized the global commercial potential of the technology and teamed up with Hector Martínez to create a technology company that would make 3D bioprinting accessible to researchers around the world by offering bioprinters, bioinks, and user-friendly software. Their breakthrough was the development of the first universal bioink that could be used with a wide range of bioprinters. This innovation democratized bioprinting by lowering both cost and technical barriers for labs interested in tissue engineering, drug discovery, and regenerative medicine.
CELLINK quickly gained international recognition, went public on the Nasdaq First North in 2016, less than a year after its founding, and expanded through both organic development and acquisitions by listening to the customer needs and expanding the portfolio through strategic acquisitions.
In 2021, CELLINK rebranded to BICO Group AB, reflecting its broader mission beyond bioprinting. Under the new name, BICO became a bioconvergence company, integrating biology, engineering, and digital technologies to accelerate innovations in life sciences.
As of 2024, our vision has expanded beyond the concept of bioconvergence, and our mission is to be the first-choice lab automation partner, and a provider of selected workflows to both pharma and biotech.
OUR VALUES
Trust
The foundation of everything we do. We build trust by fostering transparency, acting with integrity, and holding ourselves and each other accountable.
Focus
Knowing what matters most. We prioritize the goals and actions that create the greatest impact, staying committed to what drives our success.
Collaboration
Achieving more together. By working as one team, sharing knowledge, and supporting each other, we unlock our full potential and drive meaningful results across the organization.
Grit
The determination to succeed. We face challenges with passion, perseverance, and resilience, staying motivated and committed to our mission, no matter the obstacles.
Learn More
Explore what it is like to work at BICO, our open opportunities across the BICO Group, and our two business areas – Lab Automation and Life Science Solutions
